Fundamental Analysis of T2 BIOSYSTEMS INC(NASDAQ:TTOO) stock

Fundamental Rating

Overall TTOO gets a fundamental rating of 1 out of 10. We evaluated TTOO against 588 industry peers in the Biotechnology industry. Both the profitability and financial health of TTOO have multiple concerns. TTOO is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

TTOO had negative earnings in the past year.

TTOO had a negative operating cash flow in the past year.

TTOO had negative earnings in each of the past 5 years.

In the past 5 years TTOO always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -143.93%, TTOO is doing worse than 85.32% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-143.93%
ROE	N/A
ROIC	N/A

ROA(3y)-135.6%

ROA(5y)-134.62%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TTOO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TTOO does not have a ROIC to compare to the WACC, probably because it is not profitable.

TTOO has more shares outstanding than it did 1 year ago.

The number of shares outstanding for TTOO has been increased compared to 5 years ago.

The debt/assets ratio for TTOO has been reduced compared to a year ago.

2.2 Solvency

TTOO has an Altman-Z score of -28.68. This is a bad value and indicates that TTOO is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of TTOO (-28.68) is worse than 90.96% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-28.68

ROIC/WACCN/A

WACC7.49%

2.3 Liquidity

A Current Ratio of 0.45 indicates that TTOO may have some problems paying its short term obligations.

The Current ratio of TTOO (0.45) is worse than 95.39% of its industry peers.

TTOO has a Quick Ratio of 0.45. This is a bad value and indicates that TTOO is not financially healthy enough and could expect problems in meeting its short term obligations.

TTOO has a Quick ratio of 0.36. This is amonst the worse of the industry: TTOO underperforms 95.90% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.45
Quick Ratio	0.36

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TTOO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.03%, which is quite impressive.

The Revenue for TTOO has decreased by -67.75% in the past year. This is quite bad

TTOO shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.29% yearly.

EPS 1Y (TTM)90.03%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q97.25%

Revenue 1Y (TTM)-67.75%

Revenue growth 3Y-26.52%

Revenue growth 5Y-7.29%

Revenue growth Q2Q-69.36%

3.2 Future

Based on estimates for the next years, TTOO will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.95% on average per year.

TTOO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.82% yearly.

EPS Next Y65.66%

EPS Next 2Y41.33%

EPS Next 3Y21.28%

EPS Next 5Y12.95%

Revenue Next Year42.86%

Revenue Next 2Y128.97%

Revenue Next 3Y94.49%

Revenue Next 5Y63.82%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TTOO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year TTOO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as TTOO's earnings are expected to grow with 21.28% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.33%

EPS Next 3Y21.28%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for TTOO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

T2 BIOSYSTEMS INC

NASDAQ:TTOO (5/2/2024, 7:24:09 PM)

After market: 3.6799 +0.03 (+0.82%)

3.65

+0.65 (+21.67%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap20.11M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-143.93%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.21

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.45
Quick Ratio	0.36
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)90.03%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y65.66%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-67.75%

Revenue growth 3Y-26.52%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

T2 BIOSYSTEMS INC (TTOO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens